Fed. Circ. Axes Sanofi IP Claims Over Genentech Cancer Drugs
The Federal Circuit on Thursday upheld a lower court's ruling that Genentech Inc. did not infringe Sanofi-Aventis Deutschland GmbH's patents pertaining to cancer drugs Rituxan and Avastin, rejecting Sanofi's contentions that...To view the full article, register now.
Already a subscriber? Click here to view full article